Best pharmaceutical companies in Delaware

AstraZeneca is one of the world's leading pharmaceutical companies. It focuses on the discovery, development and commercialisation of prescription medicines. Its purpose is to deliver life-changing medicines by pushing the boundaries of science. AstraZenesa specializes in three main therapy areas Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory. The company operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Its headquarters in North America are located in Wilmington, DE, with additional locations in Gaithersburg, MD, and Boston, MA.

Sumitomo Dainippon Pharma America, Inc. is a holding company, which through its subsidiaries, discovers, develops, and commercializes pharmaceutical products. The company was founded in 2009 and is based in Wilmington, Delaware. Sumitomo Dainippon Pharma America, Inc. was formerly known as Dainippon Sumitomo Pharma America Holdings, Inc. and changed its name to Sumitomo Dainippon Pharma America, Inc. in July 2017. Sumitomo Dainippon Pharma America, Inc. operates as a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a tiny bioanalysis shop to a full-service CRO with 1100+ employees in the US, Europe, India and Asia. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development.

SmithKline Beecham Holdings Corporation is a holding company, which through its subsidiaries, manufactures and sells pharmaceuticals and consumer healthcare products. It also offers and dental healthcare products. The company was founded in 1996 and is based in Wilmington, Delaware. SmithKline Beecham Holdings Corporation operates as a subsidiary of SmithKline Beecham Limited.

NeuroRx is a clinical-stage pharmaceutical company that is developing NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder. NRX-101 has now entered phase 3 trials, with Breakthrough Therapy Designation and a Special Protocol Agreement from the US FDA. In phase 2 studies, NRX-101 demonstrated preliminary efficacy in treating patients with Severe Bipolar Depression and Acute Suicidal Ideation. NeuroRx draws upon 30 years of basic science and clinical expertise in the role of N-methyl-D-aspartate (NMDA), a receptor that regulates human thought processes, particularly depression and suicidality, as well as PTSD. The company is privately funded and led by former senior executives of Johnson & Johnson, BMS, Pfizer Inc., Eli Lilly, and Sunovion. NeuroRx's Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary for Planning and Evaluation, Department of the U.S. Health and Human Services; Chaim Hurvitz, former President, TEVA International Group; Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Daniel Troy, JD, former Chief Counsel, U.S. Food and Drug Administration, Hon. Abraham D. Sofaer, JD, and Lt. Gen. HR McMaster, (US Army, Ret.), the 26th US National Security Advisor.

Cannabis.Net's mission is to connect people with cannabis by offering a fully integrated media platform to support the growth of the budding marijuana industry; while providing a comprehensive resources to locate, educate, employ and entertain cannabis connoisseurs and service industry professionals. By providing a universal outlet to organize, promote and make accessible medical facilities, dispensaries, doctors and businesses to legal visitors globally, and to provide convenient access to legal entities and industry professionals, Cannabis.net is uniquely positioned to serve online media solutions for powerful advertising, brand engagement and promotion of legal marijuana products and services.

Dawah Pharmaceuticals seeks to serve the global sterile injectables and ophthalmology market by building a manufacturing facility in the US, meeting global regulatory standards. Specifically, it focuses on the sterile injectable and ophthalmic field

SPI Pharma's product portfolio addresses market trends showing an increasing call for innovative formulation, technical assistance, and troubleshooting support for antacid actives, excipients, taste-masking technology, and drug delivery systems for a v...